Trial · NCT07882953
SIMBA in Irritable Bowel Syndrome (IBS)
NCT07882953, Phase 1, Not yet recruiting, University of Calgary
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SIMBA in Irritable Bowel Syndrome (IBS). Trials, record NCT07882953. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882953
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SIMBA in Irritable Bowel Syndrome (IBS)
- NCT number
- NCT07882953
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 180 participants, estimated
- Lead sponsor
- University of Calgary
- Conditions
- Irritable Bowel Syndrome (IBS), Microbiome
- Interventions
- Rifaximin (drug), fluid biopsy capsule
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in small intestinal microbiome composition | Baseline and 4 weeks post end of treatment | Difference in small intestinal microbiome composition (Community Distance Index) within participant |
| Secondary | Change in Abdominal Pain Severity (VAS-IBS) | Baseline and 4 weeks post end of treatment | Change in participant's abdominal pain sub-score measured using the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) |
| Secondary | Difference in Dominant Microbial Composition Index Among IBS Rome V Subtypes | Baseline and 4 weeks post end of treatment | Dominant microbial composition index will be developed using shotgun metagenomic sequencing and metabolome analysis of capsule samples for each IBS sub-type (D, C and M) by collating sample results for participants by study arm. This microbial composition index for each arm will be described and differences compared. |
| Secondary | Change in Antimicrobial Resistance Gene Burden and Microbial Antimicrobial Resistance | Baseline and 4 weeks post end of treatment | Characterize intrinsic antimicrobial resistance (AMR) profiles of microbial species and subspecies identified in small intestinal samples via shotgun sequencing, measured through copy numbers of NCBI AMRFinder+ genome annotations. |
| Secondary | Predictive Accuracy of Baseline Multi-Omic Features for Clinical Response to Rifaximin | Baseline and 4 weeks post end of treatment | Microbiome feature selection and documentation (p-Values, effect size) based on Linear Mixed Effect modelling of clinical response. Model performance metrics (e.g., discrimination, calibration, and predictive accuracy) for predicting clinical response to rifaximin using baseline clinical characteristics and small intestinal multi-omic features measured via shotgun sequencing and metabolomic analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882953
GET https://conductscience.org/api/trials/v1/NCT07882953/registered